Charles River Laboratories Signs Licensing Agreement with Luminex(R) Corporation

Charles River Laboratories International, Inc.
(NYSE:CRL) (Charles River), a global provider of solutions that
advance the drug discovery and development process, and Luminex
Corporation (NASDAQ: LMNX) today announced that they have entered into
a licensing agreement whereby Charles River will utilize Luminex's
xMAP(R) technology within Charles River's Research Models and Services
business segment.
   The Luminex xMAP technology enables multiple assays to be
performed in a single well, or multiplexed, utilizing suspended
microspheres or beads. Up to 100 different simultaneous assays can be
performed in a single microtiter well, both rapidly and precisely.
Charles River's Research Animal Diagnostic Services division will use
the technology to create the Multiplexed Fluorometric ImmunoAssay
(MFIA), which will be adopted as the platform for screening laboratory
animal serum samples for infectious disease.
   William Barbo, Charles River Laboratories Corporate Vice
President, Research Model Services, said, "Charles River is pleased to
join Luminex in this licensing agreement. The use of Luminex's xMAP
technology in the form of MFIA will allow us the flexibility to
further refine and expand our assays, delivering unparalleled products
and services in the area of laboratory animal diagnostics."
   Russell Bradley, Vice President of Business Development and
Strategic Planning, Luminex Corporation, said, "We are pleased Charles
River Laboratories has selected our xMAP technology as their multiplex
platform of choice for the standardization of animal diagnostic
assays. As a market leader, Charles River Laboratories joins a growing
team of Luminex partners bringing the benefits of Luminex's bead based
multiplexing to their customers."

   About Charles River Laboratories

   Charles River Laboratories, based in Wilmington, Massachusetts,
U.S., is a global provider of solutions that advance the drug
discovery and development process. Our leading-edge products and
services are designed to enable our clients to bring drugs to market
faster and more efficiently. Backed by our rigorous, best-in-class
procedures and our proven data collection, analysis and reporting
capabilities, our products and services are organized into three
categories spanning every step of the drug development pipeline:
Research Models and Services, Preclinical Services, and Clinical
Services. Charles River's customer base includes all of the major
pharmaceutical companies and many biotechnology companies, government
agencies and leading hospitals and academic institutions. Charles
River's 8,400 employees serve clients in more than 50 countries. For
more information on Charles River, visit our website at
www.criver.com.

   About Luminex(R) Corporation

   Luminex Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the life
sciences industry. The Company's xMAP system is an open-architecture,
multi-analyte technology platform that delivers fast, accurate and
cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical
research, including the genomics and proteomics research markets. The
Company's xMAP technology is sold worldwide and is in use in leading
research laboratories as well as major pharmaceutical, diagnostic and
biotechnology companies. Luminex's xMAP technology received the 2005
Clinical Diagnostics Technology of the Year Award from Frost &
Sullivan. Further information on Luminex Corporation or xMAP can be
obtained on the Internet at http://www.luminexcorp.com or you may
contact Harriss T. Currie, Chief Financial Officer of Luminex
Corporation, [phone].